Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Outstanding (2020 - 2025)

Tarsus Pharmaceuticals has reported Shares Outstanding over the past 6 years, most recently at $42.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $42.6 million for Q4 2025, up 11.08% from a year ago — trailing twelve months through Dec 2025 was $42.6 million (up 11.08% YoY), and the annual figure for FY2025 was $42.6 million, up 11.08%.
  • Shares Outstanding for Q4 2025 was $42.6 million at Tarsus Pharmaceuticals, roughly flat from $42.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding for TARS hit a ceiling of $42.6 million in Q4 2025 and a floor of $20.5 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $30.0 million (2023), compared with a mean of $31.3 million.
  • Biggest five-year swings in Shares Outstanding: surged 675.79% in 2021 and later rose 0.95% in 2022.
  • Tarsus Pharmaceuticals' Shares Outstanding stood at $20.7 million in 2021, then grew by 29.13% to $26.7 million in 2022, then increased by 28.0% to $34.2 million in 2023, then increased by 12.1% to $38.3 million in 2024, then rose by 11.08% to $42.6 million in 2025.
  • The last three reported values for Shares Outstanding were $42.6 million (Q4 2025), $42.4 million (Q3 2025), and $42.2 million (Q2 2025) per Business Quant data.